Literature DB >> 30642917

Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms.

Shaun P Jackson1,2,3, Roxane Darbousset1,2, Simone M Schoenwaelder1,2.   

Abstract

Thrombosis with associated inflammation (thromboinflammation) occurs commonly in a broad range of human disorders. It is well recognized clinically in the context of superficial thrombophlebitis (thrombosis and inflammation of superficial veins); however, it is more dangerous when it develops in the microvasculature of injured tissues and organs. Microvascular thrombosis with associated inflammation is well recognized in the context of sepsis and ischemia-reperfusion injury; however, it also occurs in organ transplant rejection, major trauma, severe burns, the antiphospholipid syndrome, preeclampsia, sickle cell disease, and biomaterial-induced thromboinflammation. Central to thromboinflammation is the loss of the normal antithrombotic and anti-inflammatory functions of endothelial cells, leading to dysregulation of coagulation, complement, platelet activation, and leukocyte recruitment in the microvasculature. α-Thrombin plays a critical role in coordinating thrombotic and inflammatory responses and has long been considered an attractive therapeutic target to reduce thromboinflammatory complications. This review focuses on the role of basic aspects of coagulation and α-thrombin in promoting thromboinflammatory responses and discusses insights gained from clinical trials on the effects of various inhibitors of coagulation on thromboinflammatory disorders. Studies in sepsis patients have been particularly informative because, despite using anticoagulant approaches with different pharmacological profiles, which act at distinct points in the coagulation cascade, bleeding complications continue to undermine clinical benefit. Future advances may require the development of therapeutics with primary anti-inflammatory and cytoprotective properties, which have less impact on hemostasis. This may be possible with the growing recognition that components of blood coagulation and platelets have prothrombotic and proinflammatory functions independent of their hemostatic effects.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30642917     DOI: 10.1182/blood-2018-11-882993

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  145 in total

1.  Fibrin-modulating nanogels for treatment of disseminated intravascular coagulation.

Authors:  Emily P Mihalko; Megan Sandry; Nicholas Mininni; Kimberly Nellenbach; Halston Deal; Michael Daniele; Kamrouz Ghadimi; Jerrold H Levy; Ashley C Brown
Journal:  Blood Adv       Date:  2021-02-09

2.  COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET).

Authors:  Marco Marietta; Walter Ageno; Andrea Artoni; Erica De Candia; Paolo Gresele; Marina Marchetti; Rossella Marcucci; Armando Tripodi
Journal:  Blood Transfus       Date:  2020-04-08       Impact factor: 3.443

3.  Targeting AnxA1/Formyl Peptide Receptor 2 Pathway Affords Protection against Pathological Thrombo-Inflammation.

Authors:  Shantel A Vital; Elena Y Senchenkova; Junaid Ansari; Felicity N E Gavins
Journal:  Cells       Date:  2020-11-13       Impact factor: 6.600

Review 4.  Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19.

Authors:  Lucas C Godoy; Ewan C Goligher; Patrick R Lawler; Arthur S Slutsky; Ryan Zarychanski
Journal:  CMAJ       Date:  2020-08-16       Impact factor: 8.262

5.  Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo.

Authors:  Jevgenia Zilberman-Rudenko; Hiroshi Deguchi; Meenal Shukla; Yoshimasa Oyama; Jennifer N Orje; Zihan Guo; Tine Wyseure; Laurent O Mosnier; Owen J T McCarty; Zaverio M Ruggeri; Tobias Eckle; John H Griffin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-02-27       Impact factor: 8.311

Review 6.  Complementopathies and precision medicine.

Authors:  Eleni Gavriilaki; Robert A Brodsky
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 7.  Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin.

Authors:  Hiroshi Deguchi; Shravan Morla; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-10-25       Impact factor: 5.824

8.  COVID-19-Associated Carotid Atherothrombosis and Stroke.

Authors:  C Esenwa; N T Cheng; E Lipsitz; K Hsu; R Zampolin; A Gersten; D Antoniello; A Soetanto; K Kirchoff; A Liberman; P Mabie; T Nisar; D Rahimian; A Brook; S-K Lee; N Haranhalli; D Altschul; D Labovitz
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-20       Impact factor: 3.825

Review 9.  Extrapulmonary manifestations of COVID-19.

Authors:  Aakriti Gupta; Mahesh V Madhavan; Kartik Sehgal; Nandini Nair; Shiwani Mahajan; Tejasav S Sehrawat; Behnood Bikdeli; Neha Ahluwalia; John C Ausiello; Elaine Y Wan; Daniel E Freedberg; Ajay J Kirtane; Sahil A Parikh; Mathew S Maurer; Anna S Nordvig; Domenico Accili; Joan M Bathon; Sumit Mohan; Kenneth A Bauer; Martin B Leon; Harlan M Krumholz; Nir Uriel; Mandeep R Mehra; Mitchell S V Elkind; Gregg W Stone; Allan Schwartz; David D Ho; John P Bilezikian; Donald W Landry
Journal:  Nat Med       Date:  2020-07-10       Impact factor: 53.440

10.  Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy.

Authors:  Joanna Roopkumar; Shadi Swaidani; Ann S Kim; Bicky Thapa; Lorenzo Gervaso; Brian P Hobbs; Wei Wei; Tyler J Alban; Pauline Funchain; Suman Kundu; Naseer Sangwan; Patricia Rayman; Paul G Pavicic; C Marcela Diaz-Montero; John Barnard; Keith R McCrae; Alok A Khorana
Journal:  Med (N Y)       Date:  2021-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.